These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 7552520)

  • 1. Inter-Company Collaboration Combination Trials. Clinical Trial Subcommittee of the Inter-Company Collaboration for AIDS Drug Development.
    Soo W; Nauss-Karol C; Elkins M; Rooney J; Barry DW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S92-6. PubMed ID: 7552520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New combo trial/same old style.
    Gilden D
    GMHC Treat Issues; 1995 Apr; 9(4):9. PubMed ID: 11362369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future of ICC debated. Inter-Company Collaboration for AIDS Drug Development.
    Smart T
    GMHC Treat Issues; 1995 Jun; 9(6):9. PubMed ID: 11362692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug consortium seeks trial participants.
    Grodeck B
    Posit Aware; 1995; ():9. PubMed ID: 11362385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple combinations: present and future.
    Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S77-82. PubMed ID: 8595515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug companies seek trial participants.
    AIDS Alert; 1995 Jun; 10(6):82. PubMed ID: 11362432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring viral load in the clinical setting.
    Harrigan R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S34-40. PubMed ID: 8595506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Inter-Company Collaboration for AIDS Drug Development: boon or bust?
    Levin J
    BETA; 1995 Jun; ():65-6. PubMed ID: 11362548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposal: small trials for screening antiviral combinations.
    AIDS Treat News; 1995 Apr; (no 221):4-5. PubMed ID: 11362403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3.
    Kazempour K; Kammerman LA; Farr SS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S97-106. PubMed ID: 7552521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.